JP2009517337A5 - - Google Patents

Download PDF

Info

Publication number
JP2009517337A5
JP2009517337A5 JP2008536564A JP2008536564A JP2009517337A5 JP 2009517337 A5 JP2009517337 A5 JP 2009517337A5 JP 2008536564 A JP2008536564 A JP 2008536564A JP 2008536564 A JP2008536564 A JP 2008536564A JP 2009517337 A5 JP2009517337 A5 JP 2009517337A5
Authority
JP
Japan
Prior art keywords
assembly
fab
antibody
antigen
effector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008536564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517337A (ja
JP5231231B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2006/010762 external-priority patent/WO2006107617A2/en
Priority claimed from US11/389,358 external-priority patent/US7550143B2/en
Priority claimed from PCT/US2006/012084 external-priority patent/WO2006107786A2/en
Application filed filed Critical
Priority claimed from PCT/US2006/025499 external-priority patent/WO2007046893A2/en
Publication of JP2009517337A publication Critical patent/JP2009517337A/ja
Publication of JP2009517337A5 publication Critical patent/JP2009517337A5/ja
Application granted granted Critical
Publication of JP5231231B2 publication Critical patent/JP5231231B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008536564A 2005-10-19 2006-06-29 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用 Expired - Lifetime JP5231231B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US72829205P 2005-10-19 2005-10-19
US60/728,292 2005-10-19
US75119605P 2005-12-16 2005-12-16
US60/751,196 2005-12-16
US78233206P 2006-03-14 2006-03-14
US60/782,332 2006-03-14
USPCT/US2006/010762 2006-03-24
US11/389,358 2006-03-24
PCT/US2006/010762 WO2006107617A2 (en) 2005-04-06 2006-03-24 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US11/389,358 US7550143B2 (en) 2005-04-06 2006-03-24 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US11/391,584 2006-03-28
US11/391,584 US7521056B2 (en) 2005-04-06 2006-03-28 Stably tethered structures of defined compositions with multiple functions or binding specificities
USPCT/US2006/012084 2006-03-29
PCT/US2006/012084 WO2006107786A2 (en) 2005-04-06 2006-03-29 Improved stably tethered structures of defined compositions with multiple functions or binding specificities
PCT/US2006/025499 WO2007046893A2 (en) 2005-10-19 2006-06-29 Methods for generating bioactive assemblies and uses thereof

Publications (3)

Publication Number Publication Date
JP2009517337A JP2009517337A (ja) 2009-04-30
JP2009517337A5 true JP2009517337A5 (cg-RX-API-DMAC10.html) 2009-07-02
JP5231231B2 JP5231231B2 (ja) 2013-07-10

Family

ID=40666724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008536564A Expired - Lifetime JP5231231B2 (ja) 2005-10-19 2006-06-29 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用

Country Status (5)

Country Link
EP (1) EP1937851A4 (cg-RX-API-DMAC10.html)
JP (1) JP5231231B2 (cg-RX-API-DMAC10.html)
AU (1) AU2006302848C1 (cg-RX-API-DMAC10.html)
CA (1) CA2607056C (cg-RX-API-DMAC10.html)
WO (1) WO2007046893A2 (cg-RX-API-DMAC10.html)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8491914B2 (en) 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8034352B2 (en) * 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US20100226884A1 (en) 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US8883162B2 (en) 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US9862770B2 (en) 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
WO2012024223A2 (en) * 2010-08-17 2012-02-23 Immunomedics, Inc. Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
US9272029B2 (en) 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
BRPI0911427A2 (pt) * 2008-04-10 2015-11-17 Ibc Pharmaceuticals complexo por dnl (dock and lock) de anticorpo-citocina, uso de uma composição farmaceutica.
EP2305309A2 (en) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
WO2010022225A1 (en) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
EP2346526A2 (en) 2008-09-22 2011-07-27 Massachusetts Institute of Technology Compositions of and methods of using ligand dimers
MX2011005915A (es) 2008-12-03 2011-08-17 Proyecto Biomedicina Cima Sl Uso de modulinas solubles en fenol para el desarrollo de vacunas.
EP2393514B1 (en) * 2009-02-06 2017-12-20 Sichuan Huiyu Pharmaceutical Co., Ltd. Dual inhibition of immunophilin/cyclophilin and emmprin immunoglobulin receptor superfamily members
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
CA2772572A1 (en) * 2009-08-31 2011-03-03 Ibc Pharmaceuticals, Inc. Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
EP2473187A4 (en) * 2009-08-31 2015-09-16 Immunomedics Inc COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY
ES2655687T3 (es) 2009-09-11 2018-02-21 Proyecto De Biomedicina Cima, S.L. Composiciones terapéuticas para el tratamiento de enfermedades causadas por HPV
IN2012DN02692A (cg-RX-API-DMAC10.html) * 2009-11-05 2015-09-04 Ct Molecular Med & Immunology
CN102665757A (zh) * 2009-12-09 2012-09-12 免疫医疗公司 通过双特异性抗体预靶向的用于细胞毒性药物的递送系统
EP2509629A4 (en) * 2009-12-09 2013-06-26 Ibc Pharmaceuticals Inc DNL ("DOCK-AND-LOCK") COMPLEXES FOR INTERFERING RNA ADMINISTRATION
US10822396B2 (en) 2009-12-15 2020-11-03 MuHyeon CHOE Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
US20120259099A1 (en) * 2009-12-15 2012-10-11 MuHyeon CHOE Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
IN2012DN05101A (cg-RX-API-DMAC10.html) * 2010-01-19 2015-10-23 Immunomedics Inc
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
EP2588525A4 (en) 2010-06-29 2015-06-10 Covidien Lp MICROWAVE POWERED REACTOR AND IN SITU IMPLANT TRAINING METHOD
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
EP2635300A4 (en) * 2010-11-03 2014-04-02 Ibc Pharmaceuticals Inc DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
CN103160513B (zh) * 2011-12-16 2015-07-01 中国医学科学院基础医学研究所 Muc1蛋白核酸适配子、复合体、组合物及其用途
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
CN104363919A (zh) 2012-06-01 2015-02-18 Ibc药品公司 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
CN102703453B (zh) * 2012-06-13 2013-10-30 江南大学 特异性识别链霉素的dna适配体及其应用
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
ITRM20130138A1 (it) 2013-03-07 2014-09-08 Consiglio Nazionale Ricerche Assemblato comprendente un assorbitore della luce nel vicino infrarosso legato covalentemente ad un inibitore dell'anidrasi carbonica
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
CA2924520C (en) 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
FR3017714A1 (fr) * 2014-02-18 2015-08-21 Biomerieux Sa Procede et kit pour determiner la probabilite pour un patient d'evoluer vers une dengue severe
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
CN107250161A (zh) 2015-01-26 2017-10-13 宏观基因有限公司 包含dr5‑结合结构域的多价分子
CN104558174A (zh) * 2015-01-29 2015-04-29 东南大学 一种针对睾酮的特异性纳米抗体及其应用
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
CN107614515B (zh) 2015-05-28 2022-03-22 免疫医疗公司 用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
UA128469C2 (uk) 2015-10-08 2024-07-24 Макродженікс, Інк. Спосіб лікування в7-н3-експресуючого раку
EP3363447A4 (en) * 2015-10-12 2019-07-03 Industry - University Cooperation Foundation Hanyang University ADENOVIRUS COMPLEX FOR TRANSFER AND GENE THERAPY
CN108368509B (zh) * 2015-12-04 2022-03-22 全药工业株式会社 改善了血中滞留性的抗il-17适体
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
BR112019012950A2 (pt) 2016-12-23 2019-11-26 Macrogenics, Inc. molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CA3071922A1 (en) * 2017-08-04 2019-02-07 The Governing Council Of The University Of Toronto Nanoparticle platform for antibody and vaccine delivery
CN109771658B (zh) * 2017-11-14 2021-12-10 博瑞生物医药(苏州)股份有限公司 靶向多臂偶联物
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
US12252582B2 (en) 2019-08-29 2025-03-18 University Of Delaware Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス,インコーポレーテッド Cd137結合分子及びその使用
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
US20240279353A1 (en) 2020-07-06 2024-08-22 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
CN112156194B (zh) * 2020-09-29 2023-01-24 中国工程物理研究院核物理与化学研究所 一种去除177Lu溶液中内毒素的方法
CA3202233A1 (en) 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
CN115976196B (zh) * 2022-12-16 2024-12-06 深圳市人民医院 ErbB3作为肺动脉高压生物标志物和治疗靶点的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US20030198956A1 (en) * 2002-02-21 2003-10-23 Lee Makowski Staged assembly of nanostructures
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7060506B2 (en) * 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
CA2484676A1 (en) * 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
EP1563298A4 (en) * 2002-11-05 2006-12-20 Regeneron Pharma METHODS OF ISOLATING ACTIVE COMPOUNDS AND ACTIVATED TARGETS
AU2004211481A1 (en) * 2003-02-13 2004-08-26 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof
CA2604032C (en) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CN105709237A (zh) * 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体

Similar Documents

Publication Publication Date Title
JP2008538747A5 (cg-RX-API-DMAC10.html)
JP2008542194A5 (cg-RX-API-DMAC10.html)
JP7062025B2 (ja) 修飾j鎖
JP5011277B2 (ja) ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
Wang et al. Silencing Fc domains in T cell–engaging bispecific antibodies improves T-cell trafficking and antitumor potency
JP5231231B2 (ja) 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用
JP2009519931A5 (cg-RX-API-DMAC10.html)
JP5414750B2 (ja) 治療および診断用抗Hsp70抗体
CN114634569B (zh) 高亲和力b7-h6抗体和抗体片段
CN107428837A (zh) 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
CN101374546A (zh) 基于多价免疫球蛋白的生物活性装配体
CN112118892A (zh) Cd79特异性嵌合抗原受体
JP2007524686A5 (cg-RX-API-DMAC10.html)
CN110831973A (zh) 多特异性抗体及其制备和使用方法
JP2008542194A (ja) 多機能または多結合特異性を有する、改善した安定なテザー構造体の規定された組成物
JP2020188762A (ja) 細胞の細胞質への分子の送達のための構築物
Messerschmidt et al. Novel single-chain Fv′ formats for the generation of immunoliposomes by site-directed coupling
CA3173213A1 (en) Anti-cd33 antibodies and uses thereof
Faber et al. Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
JP2005510470A (ja) 二重特異性分子を用いた癌の予防、診断、および治療の方法ならびに組成物
Shinde et al. Polyvalency: an emerging trend in the development of clinical antibodies
CN114853897A (zh) 抗cd19/cd22/cd3三特异性抗体及用途
CN103159857B (zh) 以重组的三股螺旋支架为基础的复合物
CN115348973A (zh) 靶向cd33的嵌合抗原受体
CN120965882B (zh) 抗猪b细胞表面cd20的抗体或其抗原结合片段及其组合物和应用